Evidence map›Paper›PMID 32251378›Full record

ReviewMolecular psychiatry2021

Biomarkers for Alzheimer's disease-preparing for a new era of disease-modifying therapies.

Henrik Zetterberg, Barbara B Bendlin

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Molecular psychiatry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 216 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
216citing papers in PubMed, 6 pooled it
26.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

216 citing papers in PubMed, 6 syntheses or guidelines pooled it, 345 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. NeuroEPO plus (NeuralCIMAlzheimer's research & therapy · 2023
    Trial
  8. Trial
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Associations of dementia polyexposure scores to Alzheimer's disease endophenotypes in a diverse population.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  17. Review
  18. Review
  19. Article
  20. Article

156 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Henrik ZetterbergDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden. henrik.zetterberg@gu.se.
Barbara B BendlinWisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA. bbb@medicine.wisc.edu.
University of Gothenburg · SEUniversity of Wisconsin–Madison · US

Funding

Wisconsin Alzheimer's Disease Research CenterP30AG062715 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI Barbara Brigitta Bendlin · 2019 to 2026
$34.5M
Alzheimer's Disease Connectome ProjectUF1AG051216 · NIA · MEDICAL COLLEGE OF WISCONSIN · PI BENDLIN, BARBARA BRIGITTA, LI, SHI-JIANG · 2016 to 2019
$5.8M
White matter degeneration: biomarkers in preclinical Alzheimer's DiseaseR01AG037639 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI BENDLIN, BARBARA BRIGITTA · 2012 to 2023
$5.3M
SV2A PET imaging in Alzheimer's DiseaseR01AG062285 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI BENDLIN, BARBARA BRIGITTA, CHRISTIAN, BRADLEY T · 2018 to 2022
$5.3M
Neighborhood Socioeconomic Contextual Disadvantage and Alzheimer's DiseaseRF1AG057784 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI BENDLIN, BARBARA BRIGITTA, KIND, AMY J. · 2017 to 2017
$3.8M
Algebraic Formulations for Characterizing Structural Brain Connectivity Changes and Pathology Transmission Networks in Preclinical Alzheimer's DiseaseRF1AG059312 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI BENDLIN, BARBARA BRIGITTA, SINGH, VIKAS · 2019 to 2019
$1.8M
Maximizing Power in AD Clinical Trials via Multimodal Machine LearningR01AG040396 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI SINGH, VIKAS · 2012 to 2015
$1.1M
NIA NIH HHS P30 AG062715NIA NIH HHS R01 AG037639NIA NIH HHS R01 AG040396NIA NIH HHS R01 AG062285NIA NIH HHS RF1 AG057784NIA NIH HHS RF1 AG059312NIA NIH HHS UF1 AG051216
6 · The paper itself

Abstract

Clinical trial results presented in 2019 suggest that antibody-based removal of cerebral amyloid β (Aβ) plaques may possibly clear tau tangles and modestly slow cognitive decline in symptomatic Alzheimer's disease (AD). Although regulatory approval of this approach is still pending, preparing the healthcare system for the advent of disease-modifying therapies against AD is imperative. In particular, it will be necessary to identify the most suitable biomarkers to facilitate appropriate treatment of AD. Here, we give an update on recent developments in fluid and imaging biomarkers for AD-related pathologies and discuss potential approaches that could be adopted to screen for and clarify the underlying pathology in people seeking medical advice because of cognitive symptoms. We succinctly review recent data regarding biomarkers for Aβ and tau pathology, neurodegeneration, synaptic dysfunction, and inflammation, highlight the need for further research into common copathologies, and suggest how different biomarkers could be used (most likely in combination) to facilitate the development and clinical implementation of novel drug candidates against AD.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesBiomarkersCognitive DysfunctionHumansPlaque, Amyloidtau ProteinsAmyloid beta-PeptidesBiomarkerstau Proteins

Identifiers

PMID32251378
PMCPMC8172244
OpenAlexW3014879687

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.